Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow’s leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic's many resources and see jobs available for medical professionals. Get updates.
Philanthropy at Mayo ClinicYour support accelerates powerful innovations in patient care, research and education. Give today.
Search Results 21-30 of 62 for Oral
Tofacitinib Approved in 2018, tofacitinib is a selective Janus kinase (JAK) inhibitor and the first oral medication approved for treatment of moderate to severe ulcerative colitis.
Direct oral anticoagulants (DOACs) are increasingly used, and as a whole, they are more effective than warfarin in stroke prevention with a lower risk of intracerebral hemorrhage.
For more information Oral EA, et al.
Feb. 10, 2018 The gaining popularity of oral appliances Oral appliances can improve important outcomes in selected patients with more severe obstructive sleep apnea (OSA).
In this trial, a small molecule (oral agent) inhibitor of the receptor for activated complement factor 5, avacopan, is being compared head-to-head with standard glucocorticoid dosing for remission induction.
Risk factors for ONJ include: Invasive dental procedures Poor oral hygiene Prolonged anti-resorptive therapy Dr.
While the use of oral aminosalicylates and corticosteroids can be effective in suppressing the inflammatory process and inducing symptomatic remission, this approach has not been shown to alter the natural history of IBD, reduce inci...
Related Content Article The gaining popularity of oral appliances Article Getting to the heart of sleep Article Research highlights in Neurology and Neurosurgery – March 2019
Patients then receive brachytherapy, followed by oral capecitabine for two out of every three weeks while they await liver transplantation.
However, 20 percent of patients experience breakthrough episodes of VT despite treatment with oral verapamil.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.